Learn More
Background Inhibition of angiogenesis has emerged as an effective therapeutic strategy in metastatic renal cell cancer (mRCC). In this single arm phase 2 study, we evaluated the efficacy and(More)
e15153 Background: The efficacy of second-line targeted therapy (SLT) in patients with metastatic RCC who have progressed on first-line VEGFR TKI is of clinical relevance but remains to be fully(More)
  • 1